Chan KKW - Search Results

1

Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting.

Thein HH, Isaranuwatchai W, Qiao Y, Wong K, Sapisochin G, Chan KKW, Yoshida EM, Earle CC. Thein HH, et al. Among authors: chan kkw. Cancer Med. 2017 Sep;6(9):2017-2033. doi: 10.1002/cam4.1119. Epub 2017 Aug 8. Cancer Med. 2017. PMID: 28791798 Free PMC article.

2

Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.

Chan KK, Siu E, Krahn MD, Imrie K, Alibhai SM. Chan KK, et al. J Clin Oncol. 2012 Apr 1;30(10):1064-71. doi: 10.1200/JCO.2011.36.8647. Epub 2012 Mar 5. J Clin Oncol. 2012. PMID: 22393098

3

Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis.

Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, Feld JJ. Zurawska U, et al. J Clin Oncol. 2012 Sep 10;30(26):3167-73. doi: 10.1200/JCO.2011.40.7510. Epub 2012 Jun 18. J Clin Oncol. 2012. PMID: 22711851

4

Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a cost-effectiveness analysis.

Prica A, Chan K, Cheung M. Prica A, et al. Neuro Oncol. 2014 Oct;16(10):1384-91. doi: 10.1093/neuonc/nou057. Epub 2014 May 5. Neuro Oncol. 2014. PMID: 24799455 Free PMC article.

5

Cost-effectiveness analysis of staging strategies in patients with regionally metastatic melanoma.

Look Hong NJ, Petrella T, Chan K. Look Hong NJ, et al. J Surg Oncol. 2015 Mar 15;111(4):423-30. doi: 10.1002/jso.23833. Epub 2014 Nov 24. J Surg Oncol. 2015. PMID: 25422047

6

Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.

Lee EK, Wong WW, Trudeau ME, Chan KK. Lee EK, et al. Breast Cancer Res Treat. 2015 Feb;150(1):169-80. doi: 10.1007/s10549-015-3309-3. Epub 2015 Feb 19. Breast Cancer Res Treat. 2015. PMID: 25694355

7

Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.

Prica A, Chan K, Cheung M. Prica A, et al. Cancer. 2015 Aug 1;121(15):2637-45. doi: 10.1002/cncr.29372. Epub 2015 Apr 15. Cancer. 2015. PMID: 25877511 Free article.

8

Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.

Wong WW, Hicks LK, Tu HA, Pritchard KI, Krahn MD, Feld JJ, Chan KK. Wong WW, et al. Breast Cancer Res Treat. 2015 Jun;151(3):639-52. doi: 10.1007/s10549-015-3382-7. Epub 2015 May 12. Breast Cancer Res Treat. 2015. PMID: 25962692

9

Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.

Torres S, Trudeau M, Eisen A, Earle CC, Chan KKW. Torres S, et al. Among authors: chan kkw. Breast Cancer Res Treat. 2015 Jul;152(1):137-145. doi: 10.1007/s10549-015-3441-0. Epub 2015 May 31. Breast Cancer Res Treat. 2015. PMID: 26026467

10

The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.

Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Pal RS, Brezden-Masley C, Gavura S, Lien K, Chan KK. Goldhar HA, et al. J Natl Cancer Inst. 2015 Oct 16;108(1):djv301. doi: 10.1093/jnci/djv301. Print 2016 Jan. J Natl Cancer Inst. 2015. PMID: 26476433

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

324 results

Search Page

Filters